BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Li J, Hou Y, Cai XB, Liu B. Sorafenib after resection improves the outcome of BCLC stage C hepatocellular carcinoma. World J Gastroenterol 2016; 22(15): 4034-4040 [PMID: 27099447 DOI: 10.3748/wjg.v22.i15.4034] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 27] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Zeng ZM, Mo N, Zeng J, Ma FC, Jiang YF, Huang HS, Liao XW, Zhu GZ, Ma J, Peng T. Advances in postoperative adjuvant therapy for primary liver cancer. World J Gastrointest Oncol 2022; 14(9): 1604-1621 [DOI: 10.4251/wjgo.v14.i9.1604] [Reference Citation Analysis]
2 Lee HA, Seo YS, Shin I, Yoon WS, Lee HY, Rim CH. Efficacy and feasibility of surgery and external radiotherapy for hepatocellular carcinoma with portal invasion: A meta-analysis. International Journal of Surgery 2022;104:106753. [DOI: 10.1016/j.ijsu.2022.106753] [Reference Citation Analysis]
3 Tan Y, Xu Q, Wu Z, Zhang W, Li B, Zhang B, Xu X, Zhang B, Yan K, Song J, Lv T, Yang J, Jiang L, Shi Y, Yang J, Yan L. Overexpression of PD-L1 is an Independent Predictor for Recurrence in HCC Patients Who Receive Sorafenib Treatment After Surgical Resection. Front Oncol 2022;11:783335. [DOI: 10.3389/fonc.2021.783335] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Zhang ZY, Zhang EL, Zhang BX, Zhang W. Surgery for hepatocellular carcinoma with tumor thrombosis in inferior vena cava: A case report. World J Clin Cases 2021; 9(36): 11495-11503 [DOI: 10.12998/wjcc.v9.i36.11495] [Reference Citation Analysis]
5 Li Q, Song T. Association Between Adjuvant Sorafenib and the Prognosis of Patients With Hepatocellular Carcinoma at a High Risk of Recurrence After Radical Resection. Front Oncol 2021;11:633033. [PMID: 34631511 DOI: 10.3389/fonc.2021.633033] [Reference Citation Analysis]
6 Zhang ZY, Zhang EL, Zhang BX, Chen XP, Zhang W. Treatment for hepatocellular carcinoma with tumor thrombosis in the hepatic vein or inferior vena cava: A comprehensive review. World J Gastrointest Surg 2021; 13(8): 796-805 [PMID: 34512903 DOI: 10.4240/wjgs.v13.i8.796] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
7 Huang S, Li D, Zhuang L, Sun L, Wu J. A meta-analysis of the efficacy and safety of adjuvant sorafenib for hepatocellular carcinoma after resection. World J Surg Oncol 2021;19:168. [PMID: 34112190 DOI: 10.1186/s12957-021-02280-9] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 11.0] [Reference Citation Analysis]
8 Chen CZ, Zhong JH, Qi YP, Zhang J, Huang T, Ma L, Li LQ, Peng T, Xiang BD. Development of a preoperative prognostic scoring system to predict benefits of hepatic resection in advanced hepatocellular carcinoma patients. Biosci Rep 2021;41:BSR20201928. [PMID: 33835138 DOI: 10.1042/BSR20201928] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Zhang W, Zhang B, Chen XP. Adjuvant treatment strategy after curative resection for hepatocellular carcinoma. Front Med 2021;15:155-69. [PMID: 33754281 DOI: 10.1007/s11684-021-0848-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 12] [Article Influence: 8.0] [Reference Citation Analysis]
10 Lee HA, Rim CH. Efficacy of Local Treatments for Hepatocellular Carcinoma Involving the Inferior Vena Cava and/or Right Atrium. J Hepatocell Carcinoma 2020;7:435-46. [PMID: 33376712 DOI: 10.2147/JHC.S285357] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
11 Sun HC, Zhu XD, Zhou J, Gao Q, Shi YH, Ding ZB, Huang C, Qiu SJ, Ren N, Shi GM, Sun J, Ye QH, Huang XW, Yang XR, Fan J. Adjuvant apatinib treatment after resection of hepatocellular carcinoma with portal vein tumor thrombosis: a phase II trial. Ann Transl Med 2020;8:1301. [PMID: 33209881 DOI: 10.21037/atm-20-6181] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
12 Gu W, Tong Z. Sorafenib in the treatment of patients with hepatocellular carcinoma (HCC) and microvascular infiltration: a systematic review and meta-analysis. J Int Med Res 2020;48:300060520946872. [PMID: 32815430 DOI: 10.1177/0300060520946872] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
13 Huang A, Yang XR, Chung WY, Dennison AR, Zhou J. Targeted therapy for hepatocellular carcinoma. Signal Transduct Target Ther 2020;5:146. [PMID: 32782275 DOI: 10.1038/s41392-020-00264-x] [Cited by in Crossref: 127] [Cited by in F6Publishing: 141] [Article Influence: 63.5] [Reference Citation Analysis]
14 Xia Y, Zhang J, Ni X. Diagnosis, treatment and prognosis of hepatocellular carcinoma with inferior vena cava/right atrium tumor thrombus. Oncol Lett 2020;20:101. [PMID: 32831920 DOI: 10.3892/ol.2020.11962] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
15 Cerrito L, Annicchiarico BE, Iezzi R, Gasbarrini A, Pompili M, Ponziani FR. Treatment of hepatocellular carcinoma in patients with portal vein tumor thrombosis: Beyond the known frontiers. World J Gastroenterol 2019; 25(31): 4360-4382 [PMID: 31496618 DOI: 10.3748/wjg.v25.i31.4360] [Cited by in CrossRef: 53] [Cited by in F6Publishing: 56] [Article Influence: 17.7] [Reference Citation Analysis]
16 Huang Y, Zhang Z, Zhou Y, Yang J, Hu K, Wang Z. Should we apply sorafenib in hepatocellular carcinoma patients with microvascular invasion after curative hepatectomy? Onco Targets Ther. 2019;12:541-548. [PMID: 30666133 DOI: 10.2147/ott.s187357] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 6.7] [Reference Citation Analysis]
17 Fatima S, Pui-yue Lee N, Yee Kwan H, Xiang Bian Z. Emerging Targeted Therapies for Treatment of Hepatocellular Carcinoma (HCC). Hepatocellular Carcinoma - Advances in Diagnosis and Treatment 2018. [DOI: 10.5772/intechopen.71480] [Reference Citation Analysis]
18 Jue C, Zhifeng W, Zhisheng Z, Lin C, Yayun Q, Feng J, Hao G, Shintaro I, Hisamitsu T, Shiyu G, Yanqing L. Vasculogenic mimicry in hepatocellular carcinoma contributes to portal vein invasion. Oncotarget 2016;7:77987-97. [PMID: 27793002 DOI: 10.18632/oncotarget.12867] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
19 Glantzounis GK, Paliouras A, Stylianidi MC, Milionis H, Tzimas P, Roukos D, Pentheroudakis G, Felekouras E. The role of liver resection in the management of intermediate and advanced stage hepatocellular carcinoma. A systematic review. Eur J Surg Oncol. 2018;44:195-208. [PMID: 29258719 DOI: 10.1016/j.ejso.2017.11.022] [Cited by in Crossref: 32] [Cited by in F6Publishing: 41] [Article Influence: 6.4] [Reference Citation Analysis]
20 Shang J, Xu S, Zhang J, Ran X, Bai L, Tang H. Efficacy of sorafenib in patients with hepatocellular carcinoma after resection: a meta-analysis. Oncotarget 2017;8:109723-31. [PMID: 29312642 DOI: 10.18632/oncotarget.21299] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
21 Zheng L, Guo CY, Chen CS, Xiao JC, Hu HT, Cheng HT, Zong DW, Jiang L, Li HL. Sorafenib improves lipiodol deposition in transarterial chemoembolization of Chinese patients with hepatocellular carcinoma: a long-term, retrospective study. Oncotarget 2017;8:97613-22. [PMID: 29228637 DOI: 10.18632/oncotarget.18811] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
22 Zhong JH, Du XK, Xiang BD, Li LQ. Adjuvant sorafenib in hepatocellular carcinoma: A cautionary comment of STORM trial. World J Hepatol 2016; 8(23): 957-960 [PMID: 27621761 DOI: 10.4254/wjh.v8.i23.957] [Cited by in Crossref: 7] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]